Sublingual Immunotherapy (SLIT): Under-the-Tongue Allergy Treatment

Sublingual immunotherapy (SLIT) is a form of allergen desensitization that delivers controlled doses of an allergen directly under the tongue, where specialized immune cells initiate a tolerogenic response. Unlike subcutaneous immunotherapy (SCIT), which requires injections administered in a clinical setting, SLIT is designed for home administration after an initial supervised dose. This page covers the mechanism, approved forms, clinical scenarios where SLIT is indicated, and the decision thresholds that distinguish it from other treatment modalities — all within the broader landscape of allergy care available to patients across the United States.

Definition and Scope

SLIT is a disease-modifying allergy treatment — not a symptom suppressor — that works by progressively retraining the immune system to tolerate a specific allergen. Two primary product forms exist in the United States:

The U.S. Food and Drug Administration (FDA) has approved a small set of SLIT tablet products under the Biologics License Application (BLA) pathway. Approved tablets as of public FDA records include Grastek (timothy grass), Odactra (house dust mite), Ragwitek (short ragweed), and Palforzia (peanut allergy, though Palforzia is an oral immunotherapy product — distinct from sublingual drops or tablets). The regulatory context for allergy treatment in the United States establishes that compounded SLIT drops, while widely prescribed by board-certified allergists, occupy a different regulatory status than FDA-approved tablets and are not interchangeable from a regulatory standpoint.

SLIT is classified within the broader category of allergy immunotherapy, alongside subcutaneous injection therapy and oral immunotherapy (OIT).

How It Works

The mechanism of SLIT depends on the unique immunological environment beneath the tongue. The sublingual mucosa contains a high density of tolerogenic dendritic cells and regulatory T cells (Tregs). When an allergen extract is held under the tongue for 1–2 minutes before swallowing, these cells process the antigen and drive an immunological shift away from the Th2-dominant allergic response toward Th1 and regulatory pathways.

This process unfolds in three recognized phases:

  1. Induction phase (build-up): The dose is escalated over days to weeks, depending on product protocol, to reach a maintenance concentration. For FDA-approved SLIT tablets, the induction phase is typically condensed or absent — many tablets begin at the maintenance dose.
  2. Maintenance phase: The patient administers a consistent daily dose, typically for 3 to 5 years. Clinical trials supporting FDA-approved SLIT tablets — such as those submitted for Odactra and reviewed by the FDA's Allergenic Products Advisory Committee — generally used 3-year treatment durations.
  3. Post-treatment tolerance: Evidence from published trials, including data reviewed by the American Academy of Allergy, Asthma & Immunology (AAAAI), indicates that sustained post-treatment benefit requires completion of the full course.

The key immunological markers of successful SLIT include a rise in allergen-specific IgG4 (a blocking antibody), a reduction in allergen-specific IgE responsiveness, and the expansion of IL-10–secreting regulatory T cells. These changes are measurable but do not produce immediate symptom relief — most patients experience meaningful benefit between 3 and 12 months into treatment.

Common Scenarios

SLIT is indicated across several specific clinical contexts. The following scenarios reflect the population profiles where SLIT is most commonly prescribed or studied:

SLIT is not indicated for food allergies managed through standard oral immunotherapy protocols, complex multi-allergen sensitizations without a dominant driving allergen, or patients with severe, uncontrolled asthma (FEV1 < 70% predicted), in whom the risk of systemic reactions is elevated.

Decision Boundaries

Selecting SLIT over alternative modalities requires evaluating four discrete criteria:

1. Allergen specificity
SLIT demonstrates meaningful efficacy only when treatment targets an allergen confirmed by objective testing — skin prick test or specific IgE blood testing (allergy blood tests). Empirical treatment without confirmed sensitization is not supported by published evidence.

2. Severity and pharmacotherapy failure
SLIT is generally reserved for patients with persistent or moderate-to-severe symptoms who have had inadequate response to optimized pharmacotherapy, including nasal corticosteroids and antihistamines. Mild, intermittent symptoms that respond fully to medication typically do not warrant immunotherapy.

3. SLIT tablets vs. SLIT drops
The distinction between FDA-approved tablets and compounded drops carries practical weight:

Feature FDA-Approved Tablets Compounded SLIT Drops
Regulatory status BLA-approved (FDA) Off-label, compounded
Allergen coverage 3–4 specific allergens Broader, multi-allergen possible
Evidence base Phase III RCT data Observational/heterogeneous trials
Administration Once daily sublingual Once daily sublingual
Starting dose supervision Required (first dose in-office) Required (first dose in-office)

4. Patient-specific contraindications
The FDA product labeling for approved SLIT tablets lists severe, unstable, or uncontrolled asthma as a contraindication. Patients with a history of severe systemic allergic reactions or those on beta-blockers require individual evaluation by a board-certified allergist or immunologist. The AAAAI and the American College of Allergy, Asthma & Immunology (ACAAI) both publish practice parameters that define these boundaries in clinical detail.

SLIT does not replace the need for rescue medication. Patients undergoing SLIT should maintain access to epinephrine auto-injectors and have a documented allergy action plan, particularly during the induction phase when systemic reactions — though rare with sublingual routes compared to subcutaneous — remain a possibility.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)